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Abstract
Candida auris is a newly emerging species that was first identified in Asia in 2009 but has rapidly 
spread across the world. C. auris differs from most other Candida species in that antifungal 
resistance is the norm rather than the exception, it is a commensal of human skin rather than the 
human gut, and it can be easily transmitted from person to person in a healthcare setting. This 
review discusses the emergence of C. auris, global epidemiology, identification, antifungal 
susceptibility testing, and precautions to be taken when it is identified from a patient specimen.
Introduction
“Have you heard about this new Candida species, Candida auris?”
If you haven’t gotten that question yet, chances are you soon will. Candida auris was first 
described as a species in 2009 but it is still a relatively new to clinical microbiology 
laboratories [1]. The first described isolate was from the ear canal of a patient in Japan, but 
C. auris soon started showing up as a cause of bloodstream infection in other parts of Asia 
including Korea, India, and Kuwait [2–5]. Over the past eight years it has slowly started to 
emerge on other continents; first in Africa, then South America, and most recently in North 
America and Europe [6–12]. C. auris is closely related to three other rare Candida species, 
C. haemulonii, C. duobushaemulonii, and C. pseudohaemulonii in the family 
Metschnikowiaceae along with the more common Candida lusitaniae [13]. Although very 
few members of this family are known to cause human infection, those that do are known for 
their ability to develop resistance to fluconazole and amphotericin B. As will be mentioned 
below, C. auris can be difficult to distinguish from isolates of the C. haemulonii species 
complex in the clinical microbiology laboratory.
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Where in the world did C. auris originate?
Although the first reports of C. auris came out of Asia, shortly after there were subsequent 
reports of isolates from South Africa as well as Venezuela [6, 7]. One of the major questions 
surrounding C. auris was how it was able to emerge in so many countries in such a short 
time when it was essentially unheard of prior to the first report in 2009; did it emerge 
independently in each country or did a single outbreak strain spread from an original source? 
Whole-genome sequencing (WGS) and single-nucleotide polymorphism (SNP) analysis 
allow the analysis of C. auris isolates in high resolution, by characterizing genetic diversity 
of the 12.5 million base pairs in the genomes, which helps to differentiate even the most 
closely related isolates. C. auris reference genomes were assembled using two different 
types of whole genome sequencing systems, Illumina and PacBio, and those sequences were 
published and made publically available [9, 14, 15]. Using these methods and resources, 
phylogenetic trees that reveal population dynamics and structure were constructed, so that 
when coupled with the epidemiology, a better understanding of the spread of C. auris could 
be obtained.
In a study that was initiated by the Centers for Disease Control and Prevention, C. auris 
isolates from Japan, India, Pakistan, South Africa, and Venezuela were sequenced and the 
results were startling [9]. Supporting previous studies that employed more traditional 
molecular and proteomic methods, isolates were found to cluster by geography [2, 3, 16] 
(Figure 1). The remarkable finding was that isolates grouped to clusters that were nearly 
identical within the cluster, but the clusters themselves were genetically unrelated to each 
other. Specifically, four clades characterized by region (East Asian, South Asian, African, 
and South American) were identified. Each clade was separated by 40,000 – 140,000 single 
nucleotide polymorphisms (or SNPs). Within each clade, the average number of SNP 
differences between any two isolates was <70 (with many being <10), indicating a high 
degree of clonality within clades. Together, these results suggest an independent, nearly 
simultaneous emergence of four populations on three continents. Why and how this occurred 
remains unknown. Multiple independent laboratories with international culture collections 
subsequently reviewed older isolates to see if C. auris had been isolated previously and was 
either misidentified or not identified at all. While a single isolate from 1996 in Korea had 
been misidentified and a single isolate from Pakistan in 2008 had been unidentified, no other 
isolates of C. auris were identified from over 30,000 isolates from more than 40 countries 
that were reviewed [4, 9] (CDC, unpublished data). This corroborates the recent clinical 
emergence of C. auris within the last 10 years.
Combining phylogenetic analysis with epidemiology can help public health officials track 
the spread of C. auris. This has been particularly true in the United States. As of August 31, 
2016, seven U.S. cases of C. auris infection were reported to the CDC [10]. Cases were 
reported from four states; two from a single hospital in Illinois, one from Maryland, one 
from New Jersey, and three from three different hospitals in New York. WGS was performed 
on isolates from six cases, and surprisingly, isolates did not form a new clade distinct from 
the four known clades. Instead, isolates from the east coast of the United States (Maryland, 
New Jersey, and New York) clustered with the South Asian clade with a pairwise difference 
of around 60 SNPs when compared to the Indian and Pakistani isolates. As for the cases 
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from Illinois, isolates clustered with the South American clade, differing by around 150 
SNPs from the Venezuelan isolates. Although none of the cases from which isolates were 
sequenced had known travel or other direct links to South Asia or South America, the data 
suggests an original transmission link between these regions and the United States. Since the 
time of that report, the case count in the United States has increased to 33 (https://
www.cdc.gov/fungal/diseases/candidiasis/candida-auris.html; accessed 2/15/2017). 
However, all of the additional cases have been identified either in Illinois or New York, and 
each can be linked epidemiologically to a previous case. The majority of the cases of C. 
auris that have been reported either show multiple cases in a single institution, or report the 
clonal relatedness of isolates from multiple institutions [2, 3, 7–9, 11, 12, 17]. This suggests 
that there is transmission within the healthcare setting. This is unusual for Candida. 
Although outbreaks of Candida do occasionally occur, it is thought that the majority of 
Candida infections are endogenous; patients are infected with their own commensal flora. 
However, data from patient and environmental isolates suggests that transmission of C. auris 
occurs within healthcare settings [12]. During an outbreak at a hospital in England, patients 
were colonized with C. auris in multiple body sites including axilla, groin, nares, ear, 
rectum, and in urine. With the exception of C. parapsilosis, Candida is generally thought of 
as gut flora and not a skin colonizer. In addition, C. auris can be detected in the environment 
of the room of a colonized or infected patient, including on the bed, windowsills, tables 
equipment monitors, and the floor [10, 12], more like what would be expected for a bacteria 
like Clostridium difficile or an Acinetobacter and not a fungus.
The epidemiological indicators of healthcare-associated transmission are corroborated by the 
WGS data. Fewer SNP differences exist between cases who have shared a healthcare facility 
as compared to those between cases who have not shared a common facility. In the case of 
the seven reported U.S. cases, both the Maryland and New Jersey cases were at one point 
admitted to the same New Jersey hospital at the same time. These isolates differed by <10 
SNPs, which was comparable to the difference shared between the two Illinois cases that 
were admitted to the same hospital (<10 SNPs), to the difference between environmental and 
case isolates from the Illinois hospital (<5 SNPs), and also to the difference between 
multiple isolates sequenced from a single patient over a 10-day period (<6 SNPs) [10]. 
Although not as stringent as WGS, amplified fragment length polymorphism (AFLP) typing 
also indicates that isolates identified within an institution are more closely related to each 
other than isolates from other institutions [2, 3, 7, 12]
Are we going to be able to identify it in our laboratory?
Although the data presented above indicates that it has truly emerged only recently, Candida 
auris has likely been under reported due to unreliable identification [4, 18, 19]. Rare 
pathogens are often misidentified simply for the fact that they are not included in the 
databases of commercially available rapid diagnostic systems, and this has certainly been the 
case with C. auris. Unfortunately, this can delay accurate detection by clinical laboratories 
and treatment by clinicians, further compounding the underreporting in the field. To allow 
laboratories to validate their own internal identification systems and to allow commercial 
companies to get it into their databases, the CDC has recently made a panel of C. auris 
Lockhart et al. Page 3
Clin Microbiol Newsl. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
isolates and closely-related species publicly available through the FDA/CDC AR Bank 
(https://www.cdc.gov/drugresistance/resistance-bank/form/index.html).
Standard biochemical identification systems are unreliable for identifying C. auris primarily 
because they do not have C. auris in their databases. C. auris is misidentified as Candida 
haemulonii by the Vitek-2 (bioMérieux), and as Rhodotorula glutinis, Candida sake or 
Saccharomyces cerevisiae by the API 20C AUX (bioMérieux) systems [4, 9, 18]. The CDC 
panel of ten C. auris isolates with representatives from each of the four clades (as described 
above) were misidentified as C. haemulonii, except for one as C. catenulata, by BD Phoenix 
(BD Diagnostics, Sparks, MD) and they were misidentified as C. parapsilosis, C. famata, C. 
lusitaniae, and C. guillermondii by MicroScan (Beckman Coutler, Pasadena, CA) [18]. 
Users of these biochemical identification systems should realize that they may not be able to 
identify C. auris or possibly even rule it out from some of the more common Candida 
species. As these systems update their databases, accurate identifications may become 
possible. For example, bioMerieux has reported that their most recent software update for 
the VITEK 2 YST card (with Ver 8.01 software), which is just beginning to be released, 
allows the closely related species, C. auris, C. duobushaemulonii, and C. haemulonii to be 
correctly identified.
Sequencing of the internal transcribed spacer or the D1/D2 region of the ribosomal DNA 
provides accurate species level identification, but the cost, technical demands, and lengthy 
turnaround times for those without in-house sequencing capacity makes this less suitable for 
some laboratories. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) is a broad spectrum tool capable of faster and more 
accurate identification of most bacterial and fungal clinical isolates. MALDI-TOF takes a 
microbial sample input and produces a unique protein profile spectrum capable of 
discriminating microbes to the genus and species level [20]. The spectral profile is unique to 
the organisms being analyzed, and an accurate phylogenetic classification of the organism is 
automatically identified by the instrument using software to compare the spectral profile to 
reference databases. However, the important limitation to MALDI-TOF MS is that it can 
only identify organisms that are in the reference databases. A recent study comparing the 
Vitek-MS (bioMérieux) and the Bruker Biotyper (Billerica, MA) to their respective FDA-
approved libraries using the panel of ten CDC C. auris isolates found that neither instrument 
were able to identify C. auris because it was not included in the database [18]. Identification 
is possible after installing the research-use-only Saramis Version 4.14 database and 
Saccharomycetaceae update for Vitek-MS or Bruker’s 6903 MSP databases for Biotyper 
[19, 21]. CDC’s MicrobeNet (https://www.cdc.gov/microbenet/index.html) is a unique tool 
designed to provide subject matter expert-curated information for the most relevant 
identification methods in today’s laboratories, including MALDI-TOF. In collaboration with 
Bruker, MicrobeNet recently released the Biotyper Classification Module which now 
provides MicrobeNet users with access to CDC spectral libraries as well as Bruker’s most 
up-to-date database. The strains of C. auris represented in the MicrobeNet database 
represent all of the known worldwide clades and accurately classify to the species level on 
the Biotyper.
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The time until the initiation of antimicrobial treatment impacts patient mortality, so rapid 
and accurate diagnostic methods are a critical component of patient care. Historically we 
have endured lengthy turnaround times with clinical laboratories running phenotype testing 
and conventional identification methods. As most rapid candidemia treatment is empiric, the 
slower time to species identification has not been a problem. However, in the case of C. auris 
this does pose a problem because of the infection control considerations and the need to 
implement contact precautions (As will be outlined below). Infection prevention guided by 
rapid accurate detection in healthcare settings is essential for containment of this pathogen. 
MALDI-TOF MS has greatly decreased the turnaround, and it has seen rapid adoption 
worldwide, quickly becoming the standard practice in clinical microbiology [22, 23]. The 
limitations of the other identification systems, particularly with the available databases, 
should be closely monitored by lab directors, clinicians, and technologists, especially when 
it comes to emerging pathogens, because there is often a lag before these organisms are 
added to the various databases.
What about susceptibility testing, most Candida is antifungal susceptible, 
right?
The number of antifungal compounds that are available is very limited and essentially 
consists of only three classes; azoles, echinocandins, and polyenes. With this limitation in 
place, identifying species capable of developing resistance to those compounds is important 
in shaping treatment plans. Susceptibility is measured clinically as the reduction in growth in 
vitro as compared to drug-free control growth. This yields the minimum inhibitory 
concentration, or MIC, value which is used as a measure of antifungal activity. Broadly, 
Candida species are quite susceptible to antifungal drugs but exceptions include intrinsic 
fluconazole resistance in C. krusei and acquired echinocandin resistance in C. glabrata [24]. 
Approximately 6–8% of all clinical Candida isolates are resistant to fluconazole while 1% 
are resistant to the echinocandins, the majority in both categories being C. glabrata [25]. 
Amphotericin B resistance is extremely rare in Candida species with the exception of C. 
lusitaniae [26].
That being said, susceptibility testing for an emerging fungal species is complicated by the 
fact that little susceptibility information has been compiled, there are usually no breakpoints, 
and the correlation, if any, between MIC values and clinical outcome is not yet known. This 
is the case for C. auris. But by using breakpoints for other Candida species as guidance 
tentative MIC values defining resistance have been proposed (https://www.cdc.gov/fungal/
diseases/candidiasis/recommendations.html). The MIC values for a very large number of 
isolates have been determined, and the distribution contains isolates on both the higher and 
lower end of the tested range. The isolates on the lower end of the range are used to set the 
values for susceptible isolates while those on the higher end help determine the MIC at 
which an isolate may be considered resistant. While not an official breakpoint, this serves as 
a guideline to use with such an emerging species. What has been determined regarding C. 
auris and antifungal susceptibility can be summed up in three words: it is concerning.
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This species can be highly resistant to fluconazole (MIC ≥32 µg/mL), and can also show 
cross resistance to voriconazole (MIC ≥4 µg/mL) [3, 8–10, 17]. This is troubling given that 
the azoles are a mainstay in treatment of Candida infections and access to antifungals other 
than fluconazole is often poor in resource-limited countries. Some initial reports had nearly 
universal fluconazole resistance and the species was initially thought to have intrinsic 
resistance [3, 19]. However, as more isolates from around the world have been tested, 
isolates with fluconazole MIC values similar to those of C. glabrata (in the 2–8 µg/mL 
range) have been collected and fluconazole resistance is now thought to be acquired (CDC, 
unpublished data). In a recent study, 54 isolates of C. auris were analyzed for their antifungal 
susceptibilities and 93% and 33% were resistant to fluconazole and voriconazole, 
respectively [9]. In this study it was determined that the majority of the isolates with 
elevated MIC values to fluconazole and voriconazole carried mutations in the protein target 
of the azoles that had been previously shown to impact drug resistance in other Candida 
species. These mutations were geographically-distinct, with the isolates within a particular 
region having the same mutation, but different mutations for each region. Those isolates that 
did not carry such mutations had much lower MIC values to the azole drug class, suggesting 
that these isolates carried the wildtype version of this protein and were most likely 
susceptible. All reported MICs for both itraconazole and posaconazole have been relatively 
low; there are no isolates with elevated MICs which might be considered resistant. Because 
the chemical structure of intraconazole and posaconazole are somewhat different from 
fluconazole and voriconazole, it is not known whether this due to the shape of the target 
molecule or whether the isolates have just never been exposed to those two compounds 
which are rarely used to treat candidemia.
There are some isolates that exhibit resistance to one or more echinocandin (MIC ≥4 µg/mL 
for anidulafungin and micafungin, MIC ≥2 µg/mL for caspofungin) and even some with 
resistance to amphotericin B (MIC >2 µg/mL). An analysis of 102 C. auris isolates from 4 
hospitals in India reported isolates to have a 37% resistance rate to caspofungin by broth 
microdilution [19]. In fact, other reports describe several isolates from various countries with 
resistance to one or more echinocandins or with resistance to amphotericin B [7, 9, 12] To 
date, the mechanisms underlying these types of resistance are unclear. Even more 
concerning are those isolates which show in vitro resistance to all 3 major classes of 
antifungals [9]. This leaves no further option for treatment and will pose an important 
clinical challenge if C. auris increases in prevalence.
It is worth reiterating that breakpoints for C. auris are not established and what is considered 
resistant at this point should be taken as a general rule and not definitive. Clinicians should 
not necessarily rule out the use of a specific antifungal based on MIC findings; treatment 
decisions should be made on a case-by-case basis. However, the high occurrence of in vitro 
antifungal resistance among clinical isolates of C. auris is unlike what has been observed in 
other species of Candida and is a serious concern.
Is there anything else we need to consider when dealing with C. auris?
As the title of the article suggests, C. auris is not the typical Candida species. As outlined 
above, it seems to be a skin commensal rather than gut flora, development of antifungal 
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resistance seems to be the norm, and unlike the majority of Candida species, it can 
extensively contaminate healthcare environments, a scenario more typical of bacteria than 
fungi. For these considerations, the Centers for Disease Control and Prevention, and Public 
Health England each released clinical alerts, followed shortly by a Rapid risk assessment 
released by the European Centers for Disease Control (https://www.cdc.gov/fungal/diseases/
candidiasis/candida-auris-alert.html; https://www.gov.uk/government/publications/candida-
auris-laboratory-investigation-management-and-infection-prevention-and-control; http://
ecdc.europa.eu/en/publications/Publications/Candida-in-healthcare-settings_19-
Dec-2016.pdf). Each of these publications provides guidance to both clinicians and clinical 
laboratories on how to identify and report C. auris as well as infection control practices and 
environmental cleaning. The CDC recommendations are updated on a continuing basis and 
can be found here: https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html. 
Aside from what has been outlined above, the CDC recommends that patients who are 
infected or colonized by C. auris be placed under contact precautions to prevent the spread 
to other patients and to the hospital environment. This has never been a recommendation for 
any other Candida species. In addition, there is now a recommendation for daily and 
terminal cleaning with an EPA-registered hospital-grade disinfectant effective against 
Clostridium difficile spores. C. auris is not a nationally notifiable disease. However, CDC 
encourages all U.S. laboratory staff who identify C. auris strains to notify their state or local 
public health authorities and CDC at candidaauriscdc.gov.
Summary
Candida auris is the fungal equivalent of the new kid on the block. Our knowledge of this 
emerging organism is at the point where what we know about C. auris is less than what we 
do not know about C. auris. There are many important questions that remain to be answered. 
Why has it suddenly emerged? What was its prior natural niche? Will it continue to spread 
across the world? Can we decolonize people once they are colonized? With the assistance 
from clinical microbiology laboratories in the US and throughout the world, public health 
and laboratories, infection control specialists, and clinicians can begin to answer these 
questions. The first step is awareness of the problem at hand and it is hoped that this short 
review helped further your awareness and understanding of the emerging threat that is C. 
auris.
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Figure 1. 
Neighbor-joining dendrogram of whole genome sequences of Candida auris. Each color 
represents a unique country. The isolates fall into four very distinct clusters that differ 
widely from each other but are internally very clonal.
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